Study of GSK2130579A Tumor-Antigen-Specific Cancer Immunotherapeutic as Post-consolidation Therapy in Adult Patients With Acute Myeloid Leukemia

Trial Profile

Study of GSK2130579A Tumor-Antigen-Specific Cancer Immunotherapeutic as Post-consolidation Therapy in Adult Patients With Acute Myeloid Leukemia

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Aug 2016

At a glance

  • Drugs Acute myeloid leukaemia vaccine (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 28 Jul 2016 Status changed from active, no longer recruiting to completed.
    • 14 Aug 2015 Planned End Date changed from 1 Sep 2017 to 1 Jun 2016 as reported by ClinicalTrials.gov record.
    • 01 Feb 2013 Planned end date changed from 1 Oct 2016 to 1 Sep 2017 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top